Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia

Archives of Iranian Medicine

Volumn 11, Issue 3, 2008, Pages 247-251

  Yaghmaie, Marjan ^a   Ghaffari, Seyed H ^a   Ghavamzadeh, Ardashir ^a   Alimoghaddam, Kamran ^a   Jahani, Mohammad ^a   Mousavi, Seyed Asadollah ^a   Irvani, Masoud ^a   Bahar, Babak ^a   Bibordi, Isa ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

BCR ABL; Chronic myeloid leukemia; Multiplex RT PCR

Indexed keywords

BCR ABL PROTEIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; FEMALE; FUSION GENE; GENE EXPRESSION; GENE FREQUENCY; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD;

ADOLESCENT; ADULT; ARABS; CHILD; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; IRAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION, GENETIC; YOUNG ADULT;

EID: 44849129157     PISSN: 10292977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973; 243: 290-293.
2. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature. 1982; 300: 765-767.
3. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984; 36: 93-99.
4. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood. 1993; 82: 691-703
5. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996; 88: 2375-2384.
6. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985; 315: 5504-554.
7. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific p210 protein is the product of the bcrabl hybrid gene. Science. 1986; 233: 212-214.
8. Okamoto K, Karasawa M, Sakai H, Ogura H, Morita K, Naruse T. A novel acute lymphoid leukemia type BCR-ABL transcript in chronic myelogenous leukaemia. Br J Haematol. 1997; 96: 611-613.
9. Lichty BD, Keating A, Callum J, Yee K, Croxford R, Corpus G, et al. Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia. Br J Haematol. 1998; 103: 711-715.
10. Hermans A, Heisterkamp N, von Linden M, van Baal S, Meijer D, van der Plas D, et al. Unique fusion of bcr and c-abl genes in Philadelphia chromosome- positive acute lymphoblastic leukemia. Cell. 19871 51: 33-40.
11. Saglio G, Guerrasio A, Rosso C, Zaccaria A, Tassinari A, Serra A, et al. New type of BCR/ABL junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1990; 76: 1819-1824.
12. McLaughlin J, Chianese E, Witte ON. Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol Cell Biol. 1989; 9: 1866-1874.
13. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990; 247: 1079-1082.
14. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukemia in BCR/ABL transgenic mice. Nature. 1990; 344: 251-253.
15. Vardiman JW, Imbert M, Pierre R. Chronic myelogenous leukemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. International Agency for Research on Cancer. IARC Press: Lyon, France; 2001: 20-26.
16. Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, et al. Neutrophilic chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood. 1996; 88: 2410-2414.
17. van Rhee F, Lin F, Cross NC, Reid CD, Lakhani AK, Szydlo RM, et al. Detection of residual leukemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Bone Marrow Transplant. 1994; 14: 609-612.
18. Burmeister T, Maurer J, Aivado M, Elmaagacli AH, Grünebach F, Held KR, et al. Quality assurance in RT-PCR-based BCR/ABL diagnostic-results of an interlaboratory test and a standardization approach. Leukemia. 2000; 14: 1850-1856.
19. Reiter E, Greinix HT, Brugger S, Keil F, Rabitsch W, Mannhalter C, et al. Long-term follow-up after allogeneic stem cell transplantation for chronic myelogenous leukemia. Bone Marrow Transplant. 1998; 22 (supp 14): S86-S88.
20. Verschraegen CF, Kantarjian HM, Hirsch-Ginsberg C, Lee MS, O'Brien S, Rios MB, et al. The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations. Cancer. 1995; 76: 992-997.
21. Perego RA, Costantini M, Cornacchini G, Gargantini L, Bianchi C, Pungolino E, et al. The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukemia. Eur J Cancer. 2000; 36: 1395-1401.
22. Prejzner W. Relationship of the BCR gene breakpoint and the type of BCR/ ABL transcript to clinical course, prognostic indexes, and survival in patients with chronic myeloid leukemia. Med Sci Monit. 2002; 8: BR191-BR197.